Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advil, Aleve top picks

This article was originally published in The Tan Sheet

Executive Summary

Wyeth's Advil and Bayer's Aleve were identified as pain relievers of choice for back and neck pain by half of respondents in a Spine-health.com survey of OTC product preferences. Advil was the top choice in the month-long online poll, with 26 percent (236) of the 899 voters selecting the ibuprofen, according to poll results published April 23. Naproxen sodium Aleve was picked by 24 percent (216) of respondents. McNeil's Motrin ibuprofen was the choice of 13 percent (114) and the firm's Tylenol acetaminophen was picked by 11 percent (100) of participants, Spine-health.com says. Bristol-Myers Squibb's Excedrin was chosen by 6 percent (52) of respondents and aspirin 5 percent (41). Chicago-based Spine-health.com says the poll was its first seeking consumers' preferences for OTC pain relievers, although it frequently seeks reader input...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel